SIS Medical launches three innovative balloon catheters

Frauenfeld, September 05, 2018 — SIS Medical, a Swiss manufacturer of innovative cardiology products, is launching three new models of its balloon catheters. EasyT, NIC 1.1 hydro and NIC Nano hydro have characteristics that define new standards for this type of catheters. They also recently obtained approval for the CE marking. The approval will enable products to be marketed within the European Union while also facilitating registration in Asia, South America and some Middle Eastern countries, so that SIS products can also be sold there in the near future. 

SIS Medical's balloon catheters are used in interventional cardiology to dilate narrowed and closed heart vessels. This leads to full restoration of the blood flow in the diseased vessels and is providing the heart muscle with sufficient oxygen.  Patients suffering from coronary heart disease can therefore improve their physical performance or return to their job within a few days after intervention. The balloon catheters are usually advanced to the narrowed section of the blood vessels using a guide wire and catheter and then inflated with a pressure of 8 - 35 bar, thus dilating the stenosis. Conventional bypass surgery has been reduced by 80 % over the last 30 years by use of this method. 

The EasyT catheter is used to prepare the vessel prior stent implantation and for postdilation of the stent in case better stent expansion is required. Furthermore it is suitable for numerous vascular stenosis due to its small profile and trackability in tortious vessel anatomy. The common high-pressure balloon catheters currently available on the market do not have these low crossing profiles and trackability in curves. 

The products NIC 1.1 hydro and NIC Nano 0.85 hydro have the lowest crossing profile and the smallest diameters on the market and can withstand the highest pressure in vascular occlusion compared to the competition. Thanks to a special hydrophilic coating, these two catheters also feature a very smooth surface with the lowest frictional resistance, even in curved vessels. 

The three new catheters have been tested very successfully in various clinics in Germany and Switzerland. They feature an innovative new wing design for the catheter connection. This greatly facilitates identification of the appropriate balloon size and handling during interventions. 

Willi Zwahlen, Managing Director and founder of SIS Medical, explains: "After just two years at our new facility, we have developed the three new balloon catheters to market readiness. This is a great success for us and a real milestone in our product portfolio. We are consistently pursuing the goals of our internationalization strategy and can now further expand our sales activities and generate significant growth."

In 2015, the Tübingen-based SHS Gesellschaft für Beteiligungsmanagement acquired a stake in SIS Medical as part of growth financing to further expand its research and development activities and significantly increase its international market presence. An important first milestone consisted of moving to a new production facility in Frauenfeld in the Swiss canton of Thurgau at the beginning of 2016. 

About SIS Medical AG Group:

The Swiss company SIS Medical AG is an innovative manufacturer of cardiology products. SIS Medical provides doctors with innovative balloon catheters and has shown strong growth in recent years. The product portfolio includes both particularly small and particularly pressure-resistant balloon catheters, which ensure dimensional stability even at very high pressures. 

The company develops and produces its catheters in a state-of-the-art production facility in Frauenfeld, Switzerland. SIS Medical AG is majority owned by the medical technology investor SHS (www.shs-capital.eu), which has been supporting the company in its international expansion since 2015. The company's Managing Directors are co-founder and shareholder Willi Zwahlen, Patrick Looser as CFO and Dr. Fabian Eckermann as COO.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.